Hatch-Waxman and Biologics Litigation

Hatch-Waxman and Biologics Litigation

Intellectual Property Litigation

Key Contacts


  • Won a major, complete victory for Bristol-Myers Squibb and Pfizer in one of the largest Hatch-Waxman cases ever filed. A district judge found the patents covering our clients’ blockbuster drug Eliquis® were valid and infringed by all generics challenging them. This case covered 25 generic companies and likely protects Eliquis® until at least 2031. 
  • Achieved a significant victory for Shionogi when its motion for preliminary injunction was granted, preventing defendant Lupin Limited from further importation and sale of its generic copy of Shionogi's diabetes drug, Fortamet®. 
  • Obtained an important victory for Braintree Laboratories, when the Federal Circuit reversed a district court's grant of summary judgment of noninfringement for Breckenridge Pharmaceutical and remanded with instructions to enter judgment in Braintree's favor. This matter involved a patent owned by Braintree pertaining to its product Suprep®, a highly successful product designed to cleanse the colon safely before a colonoscopy.
  • Achieved a significant victory for Takeda’s wholly owned subsidiary, Millennium Pharmaceuticals, at the Federal Circuit, when the appeals court reversed a district court finding of patent invalidity and remanded the case with instructions to enter judgment in favor of Takeda. This matter involved a patent owned by the US government and exclusively licensed to Takeda covering the latter’s blockbuster oncology drug Velcade®.
  • Represented Gilead in defending the patentability of several patents related to its blockbuster Hepatitis C drugs Sovaldi® and Harvoni®. Together with co-counsel Fish & Richardson, we successfully defended all of Gilead’s challenged patents, obtaining denials of each of I-MAK’s 10 IPR petitions at the institution stage.
  • Achieved a significant victory for GlaxoSmithKline when the Federal Circuit affirmed a district judgment finding that the patent covering dutasteride, the active ingredient in GSK’s Avodart and Jalyn products, was not invalid. After a three-day bench trial, the district court had concluded that the defendants failed to prove the asserted claims invalid under any theory.


Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.